Olema Pharmaceuticals, Inc. OLMA Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -42.9%-6.3pp | -36.6%+22.6pp | -59.2%-9.5pp | -49.7%-8.1pp | -41.6%-2.5pp | |
| Return on assets | -39.4%-6.4pp | -33%+18.5pp | -51.5%-6.8pp | -44.7%-6.4pp | -38.3%-2.7pp | |
| Return on invested capital | -52.9%-2.0pp | -50.9%+24.6pp | -75.4%-13.4pp | -62%-9.0pp | -53%+9.0pp | |
| Liquidity | ||||||
| Current ratio | 10.9×+0.9× | 10×+1.9× | 8×-3.1× | 11.1×-4.1× | 15.2×+4.7× | |
| Quick ratio | 10.9×+0.9× | 10×+1.9× | 8×-3.1× | 11.1×-4.1× | 15.2×+4.7× | |
| Cash ratio | 1.1×+0.2× | 0.9×+0.1× | 0.8×-0.7× | 1.6×-0.4× | 1.9×-1.4× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $4.67-15.0% | $5.50+53.4% | $3.59-11.2% | $4.04-10.0% | $4.49-35.5% | |
| Valuation | ||||||
| Market capitalization | $973.05M+253% | $2B+198% | $671.93M+109% | $320.9M+24.9% | $256.93M-40.3% | |
| Enterprise value | $921.46M+306% | $1.96B+207% | $638.15M+136% | $270.18M+30.2% | $207.44M-29.0% | |
| Price / book | 2.1×+1.3× | 4.2×+2.0× | 2.2×+1.3× | 0.9×+0.3× | 0.7×-0.4× | |
| Earnings yield | -18.5%+27.1pp | -8.1%+14.2pp | -22.3%+22.0pp | -44.3%+5.8pp | -50.2%-20.1pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Olema Pharmaceuticals, Inc.'s ratios come from?
- Every ratio is computed from Olema Pharmaceuticals, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.